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Reduced lipid concentrations during four years of dialysis with low
molecular weight heparin. Heparin is used as standard anticoagulant in
the extracorporeal circuit of hemodialysis. Widespread use of this drug
revealed several potentially adverse effects, such as release of lipopro-
tein lipase and hepatic lipase from the endothelial surface. Recently it
was found that anticoagulatory potency and provocation of adverse
effects are linked to different subfractions of heparin. A heparin
subfraction of 4000 to 6000 Daltons rather specifically inhibits factor Xa
and therefore has a very high antithronibotic potency. Its effects on
release of lipases are minor. During a four year period five patients on
maintenance hemodialysis were treated with this low molecular weight
heparin (LMWH) subfraction. Additionally, another five patients suc-
cessively received standard heparin, LMWH and again standard hep-
arm. At all circumstances during treatment with LMWH there was a
significant (0.001 < P < 0.05) reduction both of cholesterol and
triglyceride blood concentrations. LMWH is efficient in avoiding clot-
ting in extracorporeal circuit during hemodialysis in doses of 17 to 95
U/kg (initial dose) and 7 to 20 U/kg/hr (continuous dose).
Hemodialysis became applicable after the detection of hep-
arm as an anticoagulant. Since then there have been millions of
dialysis treatments. Some side effects of this therapy, such as
serious hemorrhage [11, adverse effects on platelets [2, 31,
allergies, and effects on lipolysis [4—6] that may induce raised
serum lipid concentrations, became a problem in many patients
who were on maintenance hemodialysis.
Some years ago it was found that the antithrombotic and
anticoagulatory potency of heparin, being a mixture of polysac-
charides of different molecular weights (2,000 to 25,000 Dal-
tons), is linked to subfractions with well-defined ranges of
molecular weights. One of these low molecular weight heparin
(LMWH) subfractions (4,000 to 6,000 Daltons) shows a very
high affinity to antithrombin III, and therefore affects platelet
function less than unfractionated standard heparin [7, 8J. Be-
cause of its relatively specific effect on antithrombin Ill with a
minor influence on the activities of factors IX and XI [91,
LMWH shows low activity in broadly based anticoagulant
assays, such as PTT [4, 10, 11].
There are results of both in vitro and in vivo studies which
indicate a beneficial effect of LMWH on lipid metabolism [5].
This study was planned to elucidate long-term LMWH effects
on lipid metabolism in patients who are on maintenance hemo-
dialysis.
Methods
Long-term study
Included in this study were five patients with high cholesterol
and triglyceride concentrations, aged 47 to 65 years (mean: 53
7 years). The mean body weight was 60 9 kg. All were on
maintenance hemodialysis (3 x 4 hrs/week) at least 18 months
prior to the start of this study, and received standard heparin in
doses of 29 to 143 U/kg (initial dose) and 14 to 28 U/kg/hr
(continuous dose).
After start of this prospective, four year study, every month
blood concentrations of cholesterol and triglycerides were
determined. Occurrence of clotting of extracorporeal circuit
was documented. All other dialysis patients in our unit were
used as the control group.
Intraindis'idual ssi'itchover
Included in this study were five patients with high cholesterol
and triglyceride concentrations, aged 20 to 67 years (mean: 50
18 years). The mean body weight was 68 12 kg. All of them
were on maintenance hemodialysis (3 x 4 hrs/week) at least 18
months prior to the start of this study, and received standard
heparin in doses of 29 to 143 U/kg (initial dose) and 14 to 28
U/kg/hr (continuous dose).
After the change from standard heparin to LMWH, triglyc-
eride and cholesterol blood concentrations were controlled as in
the long-term study. After a LMWH treatment period of 12
months, each patient was switched back to the prior dosage of
standard heparin. During the following 12 months the same
controls as during LMWH period were performed.
In neither group were there additional therapeutic interven-
tions that might interfere with lipid concentrations. No patient
of the study group received any special advice on dietary
behavior or lipid reducing drugs. All blood samples were taken
directly before onset of dialysis therapy without advance noti-
fication of the patients. All dialysis sessions started four to six
hours after last food intake.
Laboratory methods
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All samples were examined in the same laboratory.
Triglyceride concentrations were determined by measure-
ment of glycerol after hydrolysis by lipase and esterase as
described [12].
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Fig. 1. Mean cholesterol concentrations during a .four year treatment
with LMWH instead of standard heparin to avoid clotiin in extracor-
poreal circuit during hemodialysi (N — 5). Symbol is: (——•—) choles-
terol.
Cholesterol concentrations were determined by an enzymatic
assay using esterase and oxidase, and measuring of hydrogen-
peroxide as described by Trinder l3].
Global coagulatory tests, such as coagulation time or deter-
mination of PTT, were done in each patient during the first four
weeks of each therapeutic regimen. Paralleling these routine
laboratory investigations, the specific antifactor Xa activity was
determined in each of the blood samples collected for mea-
suring global coagulatory potencies. For determination of spe-
cific anti-Xa activity, a commercially available kit (Coatest,
KabiVitrum, Germany) was used.
Statistics
The statistical evaluation of the data mainly was descriptive,
by calculation of the mean and SEM. Values of cholesterol and
triglyceride concentrations were compared during and at the
end of periods of application of different kinds of heparin, that
is, LMWH period versus run-in period, and in the case of
switchover study, the second standard heparin period versus
the run-in period, and second standard heparin period versus
the LMWH period. For comparison of data, the Kruskal-Wallis
test, and sign test of McNemar and test of Nemenyi were used.
Decisions were made on the basis of a 5% significance level.
Results
Throughout the study period there was no significant clotting
in the extracorporeal circuit in any patient independent of
heparin or kind of dialyzer used. The doses of LMWH used in
this study caused therapeutic levels of 0.4 to 1.0 U anti-Xa/ml.
These anti-Xa levels did not cause any prolongation of PTT and
only showed minor effects on coagulation time.
There was a significant (P < 0.05) reduction of the mean
cholesterol Concentrations throughout the study period of four
years applying LMWH compared with the prior period where
standard heparin was used (Fig. 1, Table 1). At the beginning of
the LMWH pre-treatment period the mean cholesterol concen-
tration was 220 + 34 mg/dl. At the end of the study period the
mean cholesterol concentration in serum of patients was 179
14 mg/dl.
Concomitantly there was a far more significant (P < 0.01)
drop of serum triglyceride concentrations throughout the study
period compared with pre-treatment triglyceride concentrations
(Fig. 2, Table 2). At the beginning of the pre-treatment period
there was a mean serum triglyceride concentration of 288 95
mg/dl. At the end of the four year study period there was a mean
serum triglyceride concentration of 126 9 mgldl.
To exclude accidental trends in the development of serum
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Table 1. Cholesterol concentrations during four years of
LMWH treatment
Cholesterol mgldl
1 2 3 4 5 MeansEM
280 205 215 200 200 220 34
268 203 204 200 201 215 ÷ 30
264 193 234 210 189 218 ÷ 31
289 208 212 207 205 224 36
279 209 217 212 207 225 31
266 207 225 207 212 224 26
253 205 222 209 214 221 19
257 189 207 225 198 215 27
265 184 206 218 207 216 30
262 207 202 216 205 218 25
249 212 198 214 189 212 23
259 219 212 219 207 223 + 21
260 212 217 218 210 223 21
262 207 212 207 205 219 24
258 205 202 206 189 212 + 27
262 186 200 206 187 208 31
249 185 184 188 207 203 28
234 178 182 208 [92 199 23
242 182 180 212 1196 202 26
232 169 196 178 1186 192 24
229 181 192 182 202 197 20
218 175 178 217 185 195 21
221 174 176 184 1175 186 20
225 174 176 188 201 193 21
207 176 168 178 ]L92 184 15
212 166 164 211 1L87 188 23
217 172 160 162 200 182 25
211 180 160 186 192 186 19
210 169 156 201 168 181 23
207 172 164 212 182 187 21
206 174 162 205 200 189 20
205 176 167 195 192 187 + 15
199 180 159 215 194 189 21
212 168 168 189 187 185 18
217 164 172 192 190 187 + 21
207 160 176 194 192 186 18
194 162 166 186 188 179 14
LMWH was used instead of standard heparin to avoid clotting in the
extracorporeal circuit during hemodialysis.
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Fig. 2. Mean triglyceride concentrations during a four year treatment
with LMWH instead of standard heparin to avoid clotting in extracor-
poreal circuit during hemodialysis (N — 5). Symbol is: (_s__) triglyc-
erides.
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Table 2. Triglyceride concentrations during a four year dialysis
treatment with LMWH
Patient no.
Triglycerides mgldl
1 2 3 4 5 Mean SEM
Time months
—12 405 376 222 233 204 288 95
—II 435 325 282 221 212 295 91
—10 302 260 215 205 230 242 39
—9 289 250 247 299 312 279 29
—8 293 315 245 212 300 273 43
—7 335 212 299 268 288 280 45
—6 34! 285 237 277 250 278 40
—5 421 237 235 260 235 278 81
—4 328 315 261 265 271 288 3!
—3 216 405 222 278 242 273 78
—2 217 382 218 275 289 276 68
—1 326 292 214 283 279 279 41
0 278 287 302 299 217 277 35
I 256 221 226 198 202 221 2!
2 223 254 195 182 212 213 28
3 207 247 202 172 197 205 27
4 198 227 196 178 187 197 18
5 182 192 185 168 184 182 9
6 135 176 174 154 192 166 22
7 152 178 178 138 156 160 17
8 156 186 186 143 173 169 19
9 112 189 184 136 182 161 35
10 146 198 180 119 125 154 34
II 168 146 158 13! 115 144 21
12 172 135 178 115 118 144 30
13 173 139 156 121 172 152 22
14 152 154 172 116 183 155 26
15 154 162 164 III 112 140 27
16 178 172 115 127 185 155 32
17 165 154 135 121 117 138 21
18 144 156 142 115 115 134 19
23 149 122 141 120 191 145 29
24 143 162 149 137 175 153 IS
29 122 152 150 118 150 138 17
35 127 144 132 119 114 127 12
42 135 143 III 117 121 125 13
48 125 132 127 112 136 126 9
LMWH was used instead of standard heparin to avoid clotting in the
extracorporeal circuit during hemodialysis.
concentrations of both cholesterol and of triglycerides through-
out this long term, follow-up study applying LMWH to avoid
clotting of the extracorporeal circuit, in a different group of
patients a cross over study was performed with standard
heparin and LMWH. This second group arbitrarily had marked
higher cholesterol and slightly higher triglyceride concentra-
tions than the first one.
After a run-in period of 12 months, five patients were
switched over from therapy with standard heparin to therapy
with LMWH. After another 12 months they were switched back
to the therapy with standard heparin. Immediately after onset of
therapy with LMWH there was a decline of mean cholesterol
concentration from 290 75 mg/dl (start of therapy with
LMWH) to 217 50 mgldl (end of LMWH therapy). Directly
after the second beginning of therapy with standard heparin
there was a rapid increase in mean serum cholesterol concen-
After 12 months of the second therapy with standard
heparin the mean serum cholesterol concentration was higher
than during the run-in period (329 48 mgldl vs. 290 75
mgldl). The mean serum cholesterol concentration was signifi-
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Fig. 3. Mean cholesterol concentrations during three periods of anti-
coagulation. Symbol is: (—.——) cholesterol. During the first 12 months
5 patients received standard heparin therapy. At time 0 all patients were
switched over from standard heparin to LMWH and kept on this
therapeutic regimen for another 12 months. Thereafter they were
switched back to their prior doses of standard heparin and continued
hemodialysis treatment.
anticoagulation
Patient no.
Cholesterol mgldl
I 2 3 4 5 Mean SEM
Time months
—12 255 262 272 320 375 297 50
—10 276 266 274 375 355 309 52
—8 295 284 272 359 302 302 34
—6 286 290 291 313 295 301 24
—4 279 272 251 281 408 298 62
—2 243 289 263 369 296 292 48
—1 282 287 245 412 292 304 64
0 288 275 266 406 213 290 75
1 298 26! 267 354 200 216 56
2 241 261 275 367 179 265 68
3 261 208 258 356 188 254 65
6 222 210 262 352 178 245 67
9 217 209 223 331 142 224 68
12 209 211 215 295 155 217 50
13 290 276 280 305 274 285 13
14 292 290 288 314 285 294 12
16 278 28! 279 329 291 290 22
19 301 296 294 354 308 311 25
22 301 279 310 379 317 317 37
24 305 293 317 413 316 329 48
During the first 12 months, patients received therapy with standard
heparin. At time 0, all patients were switched from standard heparin to
LMWH, and were maintained on this therapy for an additional 12
months. Then they were switched back to their prior doses of standard
heparin and continued hemodialysis treatment.
cantly (P < 0.05) lower at the end of treatment period with
LMWH compared both with run-in period and end of the
second standard heparin application (Fig. 3, Table 3).
In this cross over trial the mean serum triglyceride concen-
tration in principle showed the same course as mean serum
cholesterol concentration. Directly after switching over from
standard heparin to LMWH there was a decrease of serum
triglyceride concentrations.
This effect was reversed immediately after reapplication of
standard heparin. During this second period of therapy with
standard heparin, there was a significant (P < 0.05) rise of
serum triglyceride concentrations that overshot the concentra-
tions of the run-in period by approximately 100 mgldl in the
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Table 3. Cholesterol concentrations during three periods of
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Fig. 4. Mean triglyceride (——-) concentration during three periods of
anticoagulation. During the first 12 months 5 patients received a
therapy with standard heparin. At time 0 all patients were switched over
from standard heparin to LMWH and kept on this therapeutic regimen
for another 12 months. Thereafter they were switched back to their
prior doses of standard heparin and continued hemodialysis treatment
with standard heparin.
mean. The significantly (P < 0.05) lowest mean serum concen-
tration of triglycerides was found at the end of treatment period
with LMWH (178 77 mg/dl) compared with both the end of
the run-in period (298 112 mg/dl) and the end of new
application of standard heparin (427 148 mg/dl; Fig. 4, Table
4).
During the whole study period there were flO significant
alterations in dry body weight of patients (68 12 kg during
run-in period, 68.4 13 kg during therapy with LMWH and
67.8 15 kg during the second therapy with standard heparin)
and in mean serum phosphate concentrations (5.8 1.2 mg/dl
vs. 6.1 1.4 mg/dl vs. 5.9 1.9 mg/dl).
Discussion
The doses of LMWH used in this study caused therapeutic
levels of 0.4 to 1.0 U anti-Xa!ml without clotting independently
of the kind of dialyzer used. These anti-Xa levels did not cause
any prolongation of PTT and only showed minor effects on
coagulation time. These results correspond with those of von
Bonsdorff et al [41.
The results of this prospective clinical trial strongly support
the experimental findings that low molecular weight heparin
(LMWH) dialysis is apt to reduce high cholesterol and triglyc-
eride concentrations in serum of patients on maintenance
hemodialysis. According to our results this effect seems to
remain stable over a long time.
As shown in prior publications of Bambauer et al [14],
Deuber and Schulz [151, and Schrader, Valentin and Tönnis [61,
there are significant reductions both of cholesterol and of
triglycerides directly after the start of a low molecular weight
heparin therapy during dialysis. All published studies concern-
ing this question lack a long study period [5, 11, 14, 15]. This
study was done to attempt to close this gap.
An additional problem of most studies published so far [5, 6,
14, 15] is that there were no cross over designs. Therefore it
could not be excluded that all effects observed during the
application of low molecular weight heparin might be produced
by chance, due to alterations in dietary behavior of patients or
other intraindividual factors influencing metabolism of lipids in
the long run.
Food records were not planned in this study because it could
not be expected to get reliable nutritional data during this long
Table 4. Triglyceride concentrations during three periods of
anticoagulation
Patient no.
Triglycerides mgldl
I 2 3 4 5 Mean SEM
Time months
—12 316 265 219 296 377 295 59
—10 267 298 199 253 419 287 82
—8 273 267 208 302 403 291 72
—6 313 279 202 284 427 301 82
—4 268 270 205 276 514 307 119
—2 289 253 219 284 413 292 73
— I 256 262 256 300 445 304 81
0 238 259 206 299 489 298 112
1 218 227 195 278 423 268 92
2 186 200 197 207 390 236 86
3 176 194 165 217 395 229 95
6 168 182 152 184 390 215 99
9 165 173 149 172 326 197 73
12 127 154 135 160 314 178 77
13 188 253 329 209 480 292 118
14 315 373 343 357 535 385 87
15 402 376 407 391 539 423 66
16 418 335 421 402 557 427 81
19 289 338 347 337 539 370 97
22 343 345 335 306 596 385 119
24 372 353 355 362769 427 148
During the first 12 months, patients received therapy with standard
heparin. At time 0, all patients were switched to LMWH therapy for the
second 12 months. Then the patients were switched back to their prior
doses of standard heparin, and continued hemodialysis treatment.
study period, and because patients should not be focused on
their eating behavior. This study design should avoid bias by
not influencing the eating behavior of patients. As tentative
controls of unchanged eating behavior there were data for dry
body weights and phosphate concentrations in the blood. Even
though both parameters cannot prove unchanged fat intake they
are considered to make a marked change of diet unlikely, at
least by clinical aspects.
Additionally, in this trial a cross over design was included.
This made patients switch over from standard heparin to low
molecular weight heparin, and then after a period of 12 months,
switch back to standard heparin. The treatment period with the
second application of standard heparin also lasted 12 months.
Therefore, there was plenty of time at both therapy conditions
to examine lipid alterations that might be produced by timely
trends in dietary behavior or metabolism in patients. It is not
reasonable to argue that patients immediately changed fat
intake when heparin was changed.
At all circumstances tested there were significant drops of
mean cholesterol and of mean lipid concentrations in patients
during therapy with low molecular weight heparin compared
with standard heparin. These reduced lipid concentrations
lasted during the study period of four years. This finding is true
regardless of the degree of cholesterol or triglyceride concen-
trations. In both parts of this study there were significant
reductions of fat concentrations even though the subjects
studied showed marked differences of cholesterol concentra-
tions.
This significant reduction both of cholesterol and of triglyc-
erides might remove one of the risk factors for atherosclerosis
in those patients who are on maintenance hemodialysis, and
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therefore prevent secondary complications such as stroke or
coronary heart disease.
The biochemical hypothesis for these findings is a minor
influence of low molecular weight heparin on lipases compared
to standard heparin [5, 6].
Whether this hypothesis is sufficient for the explanation of
our findings that, after switching over from low molecular
weight heparin to standard heparin, there seems to be an
overshooting rise of lipid concentrations in patient serum yet
remains unclear. Studies should be performed to elucidate these
surprising results. Also studies are necessary to investigate
long-term changes in lipoprotein patterns in dialysis patients, as
our short-term controls during 18 months [15] suggest both a
reduction of LDL and a rise of HDL.
Reprint requests to Dr.med.Heinz Jbrgen Deuber, Institute of
Nephrology and Osteology, III.Med.Klinik, Municipal Hospital of
Bamberg, Buger Strasse 80, D-8600 Bamberg, Germany.
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